Forero-Torres, Andres <br/><br/>
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.  [electronic resource] 

 -  Blood  04 2019 
 - 1742-1752 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2018-08-867499  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Leukemia, B-Cell--drug therapy<br/>Lymphoma, B-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pyrazoles--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Pyrrolidines--administration & dosage<br/>Salvage Therapy--methods<br/>Treatment Outcome